Skip to content
Review Open access

Cell-based therapies in spinal cord injury: systematic review and meta-analysis of randomized controlled trials

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Spinal cord injury (SCI) is a severe neurological condition leading to permanent motor, sensory, and autonomic deficits, with major functional impairment and limited restorative treatment options. Cell-based therapies have emerged as a promising regenerative strategy due to their neuroprotective, immunomodulatory, and neuroregenerative properties. However, randomized controlled trials (RCTs) have reported heterogeneous results, and the overall clinical efficacy of these therapies remains uncertain. Objective: To evaluate the efficacy and safety of cell-based therapies for SCI through a systematic review and meta-analysis of randomized controlled trials. Methods: A systematic review and meta-analysis was performed using searches in PubMed, Embase, Scopus, Clinicaltrials.gov and Cochrane Library. Human RCTs comparing cell-based therapies with placebo or standard care in patients with SCI were included. Risk of bias was assessed using Cochrane RoB 2. Primary outcomes were standardized ASIA sensory and motor scores. Effects were pooled as mean differences with 95% confidence intervals using random-effects models, and heterogeneity was assessed with I² statistics. Results: Fourteen RCTs including 612 patients with follow-up ranging from 6 to 36 months were included, evaluating heterogeneous cell-based products and administration routes. Overall risk of bias was moderate. Meta-analysis demonstrated significant improvement favoring cell therapy in sensory outcomes, including light touch (WMD = 20.74, 95% CI 10.52–30.95, I² = 95.2%), pinprick (WMD = 14.61, 95% CI 6.60–22.61, I² = 89.7%), and total ASIA sensory score (WMD = 13.67, 95% CI 2.23–25.11, I² = 78.4%). Motor outcomes also favored cell therapy, including total ASIA motor score (WMD = 4.76, 95% CI 3.05–6.46, I² = 42.5%) and total impairment score (WMD = 0.77, 95% CI 0.13–1.40, I² = 86.8%). Heterogeneity ranged from moderate to high across studies, reflecting differences in cell sources, preparation methods, delivery routes, and follow-up duration. Conclusion: Cell-based therapies were associated with neurological improvement in patients with SCI, with more consistent sensory than motor recovery. However, substantial clinical and methodological heterogeneity limits definitive conclusions, highlighting the need for larger, rigorously designed RCTs with standardized protocols and longer follow-up to determine the true clinical impact of these therapies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.